Egypt’s state-owned pharmaceutical group is targeting EGP3.6bn in net profit and EGP18.9bn in revenue in the 2026/27 financial year, as it seeks to translate a multiyear overhaul of factories and its drug portfolio into stronger earnings and exports.
The Holding Company for Pharmaceuticals, Chemicals and Medical Supplies set the targets in its consolidated FY 2026/27 budget, which also calls for exports to reach $30mn. The budget was approved at a general assembly chaired by Deputy Prime Minister for Economic Affairs Hussein Eissa.
The company said the revenue target represented a 61 percent increase from actual FY 2024/25 levels, while projected net profit was about 71 percent higher than in the same comparison year.
The figures represent targets rather than realised performance and use FY2024/25 as their comparison base, leaving the group’s final FY 2025/26 results as an important benchmark for assessing the underlying pace of growth.
The targets follow a broad restructuring programme across the state pharmaceutical group, including upgrades to production machinery, laboratories, warehouses, water systems and pharmaceutical wastewater facilities as subsidiaries work to meet international Good Manufacturing Practice standards.
One of the clearest signs of an operational turnaround has come from El Nasr Pharmaceutical Chemicals, which returned to profitability for the first time in 15 years, according to the holding company.
The company also said the market value of its subsidiaries listed on the Egyptian Exchange had risen 2,514 per cent over the past four years.
The overhaul has extended beyond physical assets. Subsidiaries registered 44 new medicines during the past three years, focused on chronic and other high-demand therapeutic areas, including treatments for hypertension, diabetes and heart failure as well as antibiotics and anticoagulants. Another 124 previously discontinued medicines have been re-registered and returned to the portfolio.
The group is also rolling out an enterprise resource planning system to improve operational and financial oversight as it seeks to strengthen efficiency and transparency across its subsidiaries.
The FY2026/27 budget will test whether the group’s multiyear overhaul can translate factory upgrades and a broader drug portfolio into sustained earnings and export growth. With much of the physical modernisation under way, the next test will be commercial: raising capacity utilisation, product sales and exports.
Related news:
EGX30 Falls as Small-Caps Rise and State Listings Return to Focus
Cairo University Launches AI Policy Bulletin to Support National Planning
Read also:
EGX30 Falls as Small-Caps Rise and State Listings Return to Focus
Deutsche Telekom and Rheinmetall Partner on Advanced Counter-Drone Defence Systems
